Universita Cattolica Fondazione Policlinico Agostino Gemelli
Welcome,         Profile    Billing    Logout  
 8 Trials 
5 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fiedler, Walter
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics

Recruiting
3
882
Europe
Cytarabine, Daunorubicin, CPX-351
University of Ulm, Jazz Pharmaceuticals
Acute Myeloid Leukemia
06/27
06/27
NCT06648889: Isatuximab in Adult Patients with Cytologic or Molecular Relapsed/refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

Recruiting
2
40
Europe
Isatuximab, Bortezomib
Goethe University, Sanofi
T-ALL
02/28
08/28
AUGMENT-101, NCT04065399 / 2020-004104-34: A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Jan 2024 - Dec 2024: Market entry for acute leukemias
Hourglass Feb 2024 - Mar 2024 : Q1'24 - PDUFA date from FDA for R/R KMT2Ar acute leukemia
Dec 2022 - Dec 2023: Submission in US for relapsed/refractory acute leukemia
Jul 2023 - Sep 2023: Data from AUGMENT-101 trial for r/r AML
Checkmark Updated data from P1 portion of P1/2 AUGMENT-101 trial for AML
More
Recruiting
1/2
413
Europe, Canada, US, RoW
revumenib, SNDX-5613, cobicistat
Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
12/27
12/27
DODEKA, NCT04471987: Safety and Early Signs of Efficacy of IL12-L19L19.

Recruiting
1
94
Europe
IL12-L19L19, Dodekin
Philogen S.p.A.
Advanced Solid Tumor, Metastatic Solid Tumor
12/25
12/25
NCT04230265: Dose-escalating Trial With UniCAR02-T Cells and CD123 Target Module (TM123) in Patients With Hematologic and Lymphatic Malignancies

Recruiting
1
90
Europe
Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), TM123 (IMP), UniCAR02-T (IMP)
AvenCell Europe GmbH, PHARMALOG Institut für klinische Forschung GmbH
Acute Myeloid Leukemia (AML)
05/25
09/25

Download Options